There are very seasoned biotech investors here and seasoned biotech analysts at Oppy, Mizuho, BAML, etc.
This group is in consensus, give or take, that QCOR is a $90 stock in 2014. Add one or two positive clinical announcements, and/or the settlement of a DOJ investigation, and add an immediate $20 to the share price, or $30. Clinical announcements and an investigation settlement are all highly likely to occur in 2014.
As the share price drifts up over the next six weeks, keep that $90 figure front and center in your mind. Let's not make it easy on the short sellers, now that all of their creative but groundless short theses have been debunked.
Just in case you missed it. QCOR named one of Oppenheimer's Top Ideas for 2014.
And as reported earlier in this forum (by Mikey from memory): the truly ridiculous and irrational short thesis that all Acthar scripts were being written by a handful of doctors? Well, uh, no. Oppy asked the question at JPM: answer was less than 20 doctors wrote more than 10 scripts, 3,500 doctors wrote scripts in 2013, a very robust cross section when you consider most are specialists.
Lastly, Oppy told us that large scale buyback and aggressive M&A, both as acquirer and target, are on the evaluation list.
My advice to shorts? Hang in there, close your eyes, tough it out, stay committed, don't let $60 scare you, allow foolish shorts to cover ahead of you.
Yup. Unabashed pumping--after review last night, the QCOR JPM slides, and early anecdotes from JPM. Don Bailey and team--they came up big for shareholders IMO.
Going to enjoy the next six weeks--a lot.
The only question "left" is: how close to fair value will QCOR be at the end of February?
All the way to $90?
Or discounted a percentage due to investigation overhang and incomplete picture of IMN/ALS/ARDS/DN/lupus/etc. trials.